# LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

> **NCT03101254** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** LY3022855
- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT03101254
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-06
- **Primary completion:** 2020-10-21
- **Final completion:** 2020-11-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03101254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03101254, "LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03101254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*